Quince Therapeutics, Inc. (NASDAQ:QNCX – Get Free Report) COO Brendan Hannah bought 30,845 shares of the stock in a transaction dated Wednesday, August 21st. The shares were acquired at an average price of $0.63 per share, for a total transaction of $19,432.35. Following the completion of the purchase, the chief operating officer now directly owns 296,540 shares in the company, valued at $186,820.20. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
Brendan Hannah also recently made the following trade(s):
- On Monday, August 19th, Brendan Hannah purchased 2,155 shares of Quince Therapeutics stock. The shares were bought at an average price of $0.58 per share, with a total value of $1,249.90.
Quince Therapeutics Stock Performance
QNCX traded up $0.03 during midday trading on Wednesday, reaching $0.64. The company had a trading volume of 203,074 shares, compared to its average volume of 115,453. Quince Therapeutics, Inc. has a 12-month low of $0.51 and a 12-month high of $1.43. The business has a 50-day moving average price of $0.71 and a two-hundred day moving average price of $0.94. The stock has a market cap of $27.66 million, a PE ratio of -0.84 and a beta of 0.94. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.16 and a current ratio of 7.16.
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Read More
- Five stocks we like better than Quince Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- Energy and Oil Stocks Explained
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Most active stocks: Dollar volume vs share volume
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.